We are currently establishing a preclinical development plan for BioPace.
Treatment of chronic abnormal heart rhythm due to electrical disturbances in the upper chambers of the heart.
BioPace is an autologous cell-based therapy intended to be used as a biological pacemaker for the treatment of sino-atrial nodal dysfunction disease, a disease in which the natural pacemaker cells of the heart do not properly function due to electrical disturbances in the upper chambers of the heart and which results in an abnormal heart rhythm. The sino-atrial node is the impulse generating tissue located in the right atrium of the heart. As part of the BioPace therapy, cells from the sinoatrial node are removed from the right atrium of a patient's heart and cultured in our temperature controlled cell culturing facility. These cells are cultured in vitro in a solution containing oxygen and nutrients. While the cells are being cultured, we anticipate the patient will receive an external pacemaker to pace the remaining portions of the patient's sino-atrial node. The cultured cells are then implanted into the myocardial tissue of the right ventricle to provide biological pacing for the heart. We are currently establishing a preclinical development plan for BioPace.
Candidate |
Proposed Use or Indication |
Status/Phase |
||
|---|---|---|---|---|
| BioPace | Treatment of chronic abnormal heart rhythm due to electrical disturbances in the upper chambers of the heart. | Preclinical |
||
| Comments: Preclinical development by Bioheart. | ||||